File Download
 
 
Supplementary

Conference Paper: A staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
  • Basic View
  • Metadata View
  • XML View
TitleA staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
 
AuthorsChim, CS
Lie, AKW
Chan, EYT
Leung, YY
Cheung, SCW
Chan, SYT
Liang, R
Kwong, YL
 
Issue Date2010
 
PublisherFondazione Ferrata Storti. The Journal's web site is located at http://www.haematologica.org
 
CitationThe 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489 [How to Cite?]
 
AbstractBortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach, where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (375% paraprotein reduction) received autologous hematopoietic stem cell transplantation (auto-HSCT), whereas less VAD-sensitive patients (<75% paraprotein reduction) received bortezomib/thalidomide/dexamethasone (VTD) for further cytoreduction prior to auto-HSCT. On an intention-to treat analysis, a progressive increase of complete remission (CR) rates was observed, with cumulative CR rates of 48% after HSCT. Seven patients progressed leading to three fatalities, of which two had central nervous system disease. The 3-year overall-survival and event-free-survival (EFS) were 75.1% and 48.3%. Six patients developed oligoclonal reconstitution with new paraproteins. In the absence of anti-coagulant prophylaxis, no patients developed deep vein thrombosis. The staged application of VAD+/-VTD/auto-HSCT resulted in an appreciable response rate and promising survivals. Our approach reduced the use of bortezomib without compromising the ultimate CR rate, and is of financial significance for less affluent communities.
 
DescriptionHaematologica is supplement of the Hematology Journal
This journal supplement is Abstract Book of 15th EHA 2010
 
ISSN0390-6078
2012 Impact Factor: 5.935
2012 SCImago Journal Rankings: 1.967
 
DC FieldValue
dc.contributor.authorChim, CS
 
dc.contributor.authorLie, AKW
 
dc.contributor.authorChan, EYT
 
dc.contributor.authorLeung, YY
 
dc.contributor.authorCheung, SCW
 
dc.contributor.authorChan, SYT
 
dc.contributor.authorLiang, R
 
dc.contributor.authorKwong, YL
 
dc.date.accessioned2010-10-31T12:27:23Z
 
dc.date.available2010-10-31T12:27:23Z
 
dc.date.issued2010
 
dc.description.abstractBortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach, where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (375% paraprotein reduction) received autologous hematopoietic stem cell transplantation (auto-HSCT), whereas less VAD-sensitive patients (<75% paraprotein reduction) received bortezomib/thalidomide/dexamethasone (VTD) for further cytoreduction prior to auto-HSCT. On an intention-to treat analysis, a progressive increase of complete remission (CR) rates was observed, with cumulative CR rates of 48% after HSCT. Seven patients progressed leading to three fatalities, of which two had central nervous system disease. The 3-year overall-survival and event-free-survival (EFS) were 75.1% and 48.3%. Six patients developed oligoclonal reconstitution with new paraproteins. In the absence of anti-coagulant prophylaxis, no patients developed deep vein thrombosis. The staged application of VAD+/-VTD/auto-HSCT resulted in an appreciable response rate and promising survivals. Our approach reduced the use of bortezomib without compromising the ultimate CR rate, and is of financial significance for less affluent communities.
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionHaematologica is supplement of the Hematology Journal
 
dc.descriptionThis journal supplement is Abstract Book of 15th EHA 2010
 
dc.description.otherThe 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489
 
dc.identifier.citationThe 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489 [How to Cite?]
 
dc.identifier.epage593
 
dc.identifier.hkuros172211
 
dc.identifier.issn0390-6078
2012 Impact Factor: 5.935
2012 SCImago Journal Rankings: 1.967
 
dc.identifier.issues2
 
dc.identifier.spage593
 
dc.identifier.urihttp://hdl.handle.net/10722/126416
 
dc.identifier.volume95
 
dc.languageeng
 
dc.publisherFondazione Ferrata Storti. The Journal's web site is located at http://www.haematologica.org
 
dc.publisher.placeItaly
 
dc.relation.ispartofHaematologica: the Hematology Journal
 
dc.titleA staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chim, CS</contributor.author>
<contributor.author>Lie, AKW</contributor.author>
<contributor.author>Chan, EYT</contributor.author>
<contributor.author>Leung, YY</contributor.author>
<contributor.author>Cheung, SCW</contributor.author>
<contributor.author>Chan, SYT</contributor.author>
<contributor.author>Liang, R</contributor.author>
<contributor.author>Kwong, YL</contributor.author>
<date.accessioned>2010-10-31T12:27:23Z</date.accessioned>
<date.available>2010-10-31T12:27:23Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489</identifier.citation>
<identifier.issn>0390-6078</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/126416</identifier.uri>
<description>Haematologica is supplement of the Hematology Journal</description>
<description>This journal supplement is Abstract Book of 15th EHA 2010</description>
<description.abstract>Bortezomib-based regimens have significant activities in multiple myeloma (MM). In this study, we tested the efficacy of a total therapy with a staged approach, where newly diagnosed MM patients received vincristine/adriamycin/dexamethsone (VAD). VAD-sensitive patients (375% paraprotein reduction) received autologous hematopoietic stem cell transplantation (auto-HSCT), whereas less VAD-sensitive patients (&lt;75% paraprotein reduction) received bortezomib/thalidomide/dexamethasone (VTD) for further cytoreduction prior to auto-HSCT. On an intention-to treat analysis, a progressive increase of complete remission (CR) rates was observed, with cumulative CR rates of 48% after HSCT. Seven patients progressed leading to three fatalities, of which two had central nervous system disease. The 3-year overall-survival and event-free-survival (EFS) were 75.1% and 48.3%. Six patients developed oligoclonal reconstitution with new paraproteins. In the absence of anti-coagulant prophylaxis, no patients developed deep vein thrombosis. The staged application of VAD+/-VTD/auto-HSCT resulted in an appreciable response rate and promising survivals. Our approach reduced the use of bortezomib without compromising the ultimate CR rate, and is of financial significance for less affluent communities.</description.abstract>
<language>eng</language>
<publisher>Fondazione Ferrata Storti. The Journal&apos;s web site is located at http://www.haematologica.org</publisher>
<relation.ispartof>Haematologica: the Hematology Journal</relation.ispartof>
<title>A staged approach with vincristine, adriamycin and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma</title>
<type>Conference_Paper</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.hkuros>172211</identifier.hkuros>
<identifier.volume>95</identifier.volume>
<identifier.issue>s2</identifier.issue>
<identifier.spage>593</identifier.spage>
<identifier.epage>593</identifier.epage>
<publisher.place>Italy</publisher.place>
<description.other>The 15th Congress of the European Hematology Association (EHA), Barcelona, Spain, 10-13 June 2010. In Haematologica, 2010, v. 95 n. s2, p. 593, abstract no. 1489</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/126416/3/re01.htm</bitstream.url>
</item>